# Ovarian cancer diagnosis and treatment

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers encompasses an extensive exploration of ovarian cancer, including genomic analyses, treatment strategies such as chemotherapy and cytoreductive surgery, identification of biomarkers, investigation of tumor models, mutation analysis, the role of fallopian tube origin in cancer development, metastasis patterns, and insights from clinical trials. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t10550 |
| Works | 431 |

## Topic papers all

Showing 15 of 431.

- [Integrated genomic analyses of ovarian carcinoma](https://scholariq.org/papers/integrated-genomic-analyses-of-ovarian-carcinoma/)
- [Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers](https://scholariq.org/papers/inhibition-of-poly-adp-ribose-polymerase-in-tumors-from-i-brca-i-mutation/)
- [Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer](https://scholariq.org/papers/maintenance-olaparib-in-patients-with-newly-diagnosed-advanced-ovarian-cancer/)
- [Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer](https://scholariq.org/papers/concurrent-cisplatin-based-radiotherapy-and-chemotherapy-for-locally-advanced/)
- [Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer](https://scholariq.org/papers/intraperitoneal-cisplatin-and-paclitaxel-in-ovarian-cancer/)
- [Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer](https://scholariq.org/papers/neoadjuvant-chemotherapy-or-primary-surgery-in-stage-iiic-or-iv-ovarian-cancer/)
- [Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer](https://scholariq.org/papers/niraparib-maintenance-therapy-in-platinum-sensitive-recurrent-ovarian-cancer/)
- [Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer](https://scholariq.org/papers/incorporation-of-bevacizumab-in-the-primary-treatment-of-ovarian-cancer/)
- [Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial](https://scholariq.org/papers/oral-poly-adp-ribose-polymerase-inhibitor-olaparib-in-patients-with-brca1-or/)
- [Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer](https://scholariq.org/papers/niraparib-in-patients-with-newly-diagnosed-advanced-ovarian-cancer/)
- [A Phase 3 Trial of Bevacizumab in Ovarian Cancer](https://scholariq.org/papers/a-phase-3-trial-of-bevacizumab-in-ovarian-cancer/)
- [Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer](https://scholariq.org/papers/olaparib-plus-bevacizumab-as-first-line-maintenance-in-ovarian-cancer/)
- [Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study](https://scholariq.org/papers/phase-iii-trial-of-carboplatin-and-paclitaxel-compared-with-cisplatin-and/)
- [ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma](https://scholariq.org/papers/esgo-estro-esp-guidelines-for-the-management-of-patients-with-endometrial/)
- [Epithelial ovarian cancer](https://scholariq.org/papers/epithelial-ovarian-cancer/)

## Topic primary papers

Showing 15 of 193.

- [Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer](https://scholariq.org/papers/intraperitoneal-cisplatin-and-paclitaxel-in-ovarian-cancer/)
- [Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer](https://scholariq.org/papers/neoadjuvant-chemotherapy-or-primary-surgery-in-stage-iiic-or-iv-ovarian-cancer/)
- [Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer](https://scholariq.org/papers/incorporation-of-bevacizumab-in-the-primary-treatment-of-ovarian-cancer/)
- [A Phase 3 Trial of Bevacizumab in Ovarian Cancer](https://scholariq.org/papers/a-phase-3-trial-of-bevacizumab-in-ovarian-cancer/)
- [Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study](https://scholariq.org/papers/phase-iii-trial-of-carboplatin-and-paclitaxel-compared-with-cisplatin-and/)
- [Epithelial ovarian cancer](https://scholariq.org/papers/epithelial-ovarian-cancer/)
- [Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial](https://scholariq.org/papers/bevacizumab-combined-with-chemotherapy-for-platinum-resistant-recurrent-ovarian/)
- [Rethinking ovarian cancer: recommendations for improving outcomes](https://scholariq.org/papers/rethinking-ovarian-cancer-recommendations-for-improving-outcomes/)
- [Epithelial ovarian cancer: Evolution of management in the era of precision medicine](https://scholariq.org/papers/epithelial-ovarian-cancer-evolution-of-management-in-the-era-of-precision/)
- [OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer](https://scholariq.org/papers/oceans-a-randomized-double-blind-placebo-controlled-phase-iii-trial-of/)
- [Ovarian cancer](https://scholariq.org/papers/ovarian-cancer/)
- [Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial](https://scholariq.org/papers/paclitaxel-plus-platinum-based-chemotherapy-versus-conventional-platinum-based/)
- [ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease](https://scholariq.org/papers/esmo-esgo-consensus-conference-recommendations-on-ovarian-cancer-pathology-and/)
- [Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://scholariq.org/papers/newly-diagnosed-and-relapsed-epithelial-ovarian-carcinoma-esmo-clinical-practice/)
- [Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial](https://scholariq.org/papers/ovarian-cancer-screening-and-mortality-in-the-uk-collaborative-trial-of-ovarian/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.